A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients
Hai Feng(Chinese University of Hong Kong), Alfred S.L. Cheng(Chinese University of Hong Kong), Henry Lik‐Yuen Chan(Radiant Research (United States)), May S. Li, Joseph J.�Y. Sung(Nanyang Technological University), Yuan Tian(Duke University), Ka‐Fai To(Chinese University of Hong Kong), Zhuo Yu(University of North Carolina at Chapel Hill), Ying‐Ying Lee(Chinese University of Hong Kong), Andrew M. Chan(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Minnie Y.Y. Go(Therapeutics Clinical Research), Yue S. Cheung(Chinese University of Hong Kong)
Cited by 76
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895